Top 40+ Pharmaceutical Companies In Boston In 2021
← Visit blog

Top 40+ Pharmaceutical Companies In Boston In 2021

Updated on March 11th, 2021

Top 40+ Pharmaceutical Companies In Boston In 2021

A hand curated list of 40+ top pharmaceutical companies in Boston.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Centrexion ($1M to $10M)
  2. Cerevel Therapeutics ($1M to $10M)
  3. Rhythm Pharmaceuticals ($1M to $10M)
  4. Pieris Pharmaceuticals ($10M to $50M)
  5. Inozyme ($10M to $50M)
  6. AZTherapies (Less than $1M)
  7. Clinical Research IO ($1M to $10M)
  8. Symbiosis Pharmaceutical Services ($1M to $10M)
  9. Imbria Pharmaceuticals ($1M to $10M)
  10. Manifold Bio ($10M to $50M)
  11. Stargazer Pharmaceuticals (Less than $1M)
  12. IGC BIO ($10M to $50M)
  13. GRO Biosciences (Less than $1M)
  14. Anodyne Nanotech (Less than $1M)
  15. Xontogeny (Less than $1M)
  16. BioAnalytix (Less than $1M)
  17. resTORbio ($1M to $10M)
  18. Compass Therapeutics ($10M to $50M)
  19. ConcertAI ($10M to $50M)
  20. Syntimmune ($10M to $50M)
  21. Alloplex Biotherapeutics (Less than $1M)
  22. Bioarray Therapeutics (Less than $1M)
  23. Particles for Humanity (Less than $1M)
  24. Pyxis Oncology ($10M to $50M)
  25. Ginkgo Bioworks ($10M to $50M)
  26. Back Bay Life Science Advisors (Less than $1M)
  27. Prilenia (Less than $1M)
  28. Eliem Therapeutics ($1M to $10M)
  29. Exonics Therapeutics ($1M to $10M)
  30. Kumuda ($10M to $50M)
  31. Karuna Therapeutics ($1M to $10M)
  32. Reverie Labs (Less than $1M)
  33. Flaskworks ($1M to $10M)
  34. Atea Pharmaceuticals ($1M to $10M)
  35. Flex Pharma (Less than $1M)
  36. Cardurion Pharmaceuticals ($10M to $50M)
  37. Resilience Therapeutics ($10M to $50M)
  38. Farcast ($1M to $10M)
  39. CONTINUUS Pharmaceuticals (Less than $1M)
  40. Silicon Therapeutics (Less than $1M)
  41. Entrega Bio (Less than $1M)
  42. Acetylon Pharmaceuticals ($1M to $10M)
  43. QMENTA ($1M to $10M)
  44. Samsara Therapeutics ($1M to $10M)
  45. Invetx ($10M to $50M)
  46. Akouos ($1M to $10M)
  47. TearClear ($1M to $10M)
  48. Alkeus Pharmaceuticals ($1M to $10M)


  1. Centrexion ($1M to $10M)

    Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40.5M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. brown wooden table and chairs


  3. Cerevel Therapeutics ($1M to $10M)

    Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $350M raised in October, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. tennis table in room


  5. Rhythm Pharmaceuticals ($1M to $10M)

    Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $172.5M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. three women sitting around table using laptops


  7. Pieris Pharmaceuticals ($10M to $50M)

    Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $32M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. brown and white table and chairs


  9. Inozyme ($10M to $50M)

    Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $67.4M raised in April, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. rolling armchair beside table


  11. AZTherapies (Less than $1M)

    AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 11-50 employees
    • $14.8M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  12. people using desktop computer inside office


  13. Clinical Research IO ($1M to $10M)

    Clinical Research IO is a fast-growing health tech company, bringing clinical trial software to a largely paper-based process. With CRIO's leading eSource (electronic Source), research investigators create e-source templates and use a mobile tablet to capture clinical trial source data, saving them time and improving accuracy. Procedures link to CRIO's Clinical Trial Management System (CTMS), which includes patient recruiting, scheduling and financial management. Lastly, regulatory documents are managed and storied electronically in CRIO's user-friendly eRegulatory. CRIO has offices in Boston and San Francisco.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.4M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  14. group of people sitting beside rectangular wooden table with laptops


  15. Symbiosis Pharmaceutical Services ($1M to $10M)

    Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials. We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products. Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  16. two men using computers


  17. Imbria Pharmaceuticals ($1M to $10M)

    Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40.7M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  18. Manifold Bio ($10M to $50M)

    Manifold Bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement-driven design. The company is building a protein barcoding platform to bring the power of multiplexed measurement to the development of protein therapeutics. It was founded in 2020 and headquartered in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $5.4M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  19. man in gray sweatshirt sitting on chair in front of iMac


  20. Stargazer Pharmaceuticals (Less than $1M)

    Stargazer Pharmaceuticals is a pharmaceutical company that offers the therapy of standards disorder and manufacturer of pharmaceuticals products. It's also a Manufacturer of pharmaceuticals. The company is currently operating in Stealth mode.

    • Less than $1M annual revenues
    • 1-10 employees
    • $57M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  21. people sitting on black chairs


  22. IGC BIO ($10M to $50M)

    IGC BIO is a biotechnology company based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.2M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  23. people sitting in front of computer monitors


  24. GRO Biosciences (Less than $1M)

    GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3.5M raised in March, 2019
    • 7 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  25. people sitting beside rectangular brown table with laptops


  26. Anodyne Nanotech (Less than $1M)

    Anodyne Nanotech is a preclinical-stage biotech company that develops differentiated, transdermal forms of high-value drugs. The company’s first practical and cost-effective platform, Hero Patch, delivers clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules for fast and sustained delivery. Anodyne Nanotech was founded in 2019 by Jake Lombardo, Konstantinos Tzortzakis, and Hojatollah Rezaei Nejad.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  27. people standiunmg


  28. Xontogeny (Less than $1M)

    Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with the founding scientists and entrepreneurs of new ventures to support their vision while allowing a more efficient development model to benefit company founders and early equity holders.

    • Less than $1M annual revenues
    • 11-50 employees
    • $15M raised in May, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  29. BioAnalytix (Less than $1M)

    Bioanalytix is a pharmaceutically oriented commercial spin out from the Barnett institute of chemical and Biological Analysis at Northeastern university in Boston,MA. Founded by thought leaders in clinical development, regulatory strategy, and advanced analytics,Bioanaytix is working wiht leading Pharmaceutical partners to advance, improve and accelerate the development and commercialization of biologic and biosimilar drugs.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3.8M raised in October, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  30. selective focus photography of desk lamp on table


  31. resTORbio ($1M to $10M)

    resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40M raised in November, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  32. grey wooden table and black leather rolling chairs


  33. Compass Therapeutics ($10M to $50M)

    Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Boston Landing, Mass.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $60.5M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  34. rectangular brown wooden table with chair lot inside building


  35. ConcertAI ($10M to $50M)

    ConcertAI is a developer of medical research tool suite intended to design and deliver care-based oncology research and data analytics. It is an integrated real-world data and AI-driven solutions to transform how insights are generated and accelerate therapeutic innovations to patients. It was incorporated in 2018 and is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 5001-10000 employees
    • $150M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  36. photo of industrial machines near table


  37. Syntimmune ($10M to $50M)

    Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $50M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  38. people sitting and using laptops


  39. Alloplex Biotherapeutics (Less than $1M)

    Alloplex Biotherapeutics is a privately held Boston based cellular therapeutics company. Their lead oncology therapeutic is a PBMC-derived multicellular adoptive immunotherapy which they call SUPLEXA cells. They use proprietary leukocyte activator cell lines (ENLiST cells), which are engineered from a common tumor cell line to express an array of immunomodulatory ligands designed to specifically engage and activate various subsets of peripheral blood mononuclear cells (PBMC) through their native receptors. Alloplex has developed SUPLEXA cells through the use of an all-human in vitro assay which not only models the intended ex vivo activation of patient PBMC but is, in fact, the actual procedure to be deployed in the clinic. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  40. people having meeting on rectangular brown table


  41. Bioarray Therapeutics (Less than $1M)

    BIOARRAY's Therapeutics, Inc. (BIOARRAY) is a privately held start up biotechnology company founded in 2009 in Boston, MA. BIOARRAY is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4M raised in October, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  42. rectangular brown wooden table


  43. Particles for Humanity (Less than $1M)

    Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  44. men sitting of chair inside room


  45. Pyxis Oncology ($10M to $50M)

    Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $22M raised in July, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  46. man in black jacket sitting on chair


  47. Ginkgo Bioworks ($10M to $50M)

    Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Gingko Bioworks also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $70M raised in May, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  48. man and woman sitting at table


  49. Back Bay Life Science Advisors (Less than $1M)

    Back Bay Life Science Advisors provides strategy consulting and transaction advisory services to the life science industry. Our expertise spans the continuum of stage, sector, and geography, across every therapeutic class. We work with local and global biopharmaceutical and medical technology sectors on the buy and sell side of transaction execution, from gleam-in-the-eye preclinical technology platforms to $2 billion established brands.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.6M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  50. men using computers


  51. Prilenia (Less than $1M)

    Prilenia is a provider of biotechnology services. Improving the lives of patients and their families, by developing treatments for neurodegenerative and neurodevelopmental disorders, lies at the heart of Prilenia’s mission.

    • Less than $1M annual revenues
    • 1-10 employees
    • $62.5M raised in June, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  52. two women sitting beside table using MacBooks


  53. Eliem Therapeutics ($1M to $10M)

    Eliem Therapeutics will leverage our world-class expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. We are pioneering a new generation of analgesics to facilitate a better quality of life for patients.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $5M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  54. people sitting on chairs near tables during daytime


  55. Exonics Therapeutics ($1M to $10M)

    Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40M raised in November, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  56. grayscale photo of people in room


  57. Kumuda ($10M to $50M)

    Our powerful computational platform expands the small molecule drug target space to efficiently push discovery efforts towards successful first-in-class drugs in the clinic.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. architectural photo of buildings during daytime


  59. Karuna Therapeutics ($1M to $10M)

    Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $68M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. brown wooden table and chairs


  61. Reverie Labs (Less than $1M)

    Reverie Labs (YC W18) is building a pharma company from scratch, using computation. Reverie Labs accelerates preclinical drug development by applying machine learning to lead generation & optimization.

    • Less than $1M annual revenues
    • 1-10 employees
    • $25M raised in February, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. tennis table in room


  63. Flaskworks ($1M to $10M)

    Flaskworks is improves the manufacture of immuno-therapeutics and dendritic cell-based vaccines.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.2M raised in September, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. three women sitting around table using laptops


  65. Atea Pharmaceuticals ($1M to $10M)

    Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $215M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. brown and white table and chairs


  67. Flex Pharma (Less than $1M)

    Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated.

    • Less than $1M annual revenues
    • 11-50 employees
    • $40M raised in September, 2014
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. rolling armchair beside table


  69. Cardurion Pharmaceuticals ($10M to $50M)

    Cardurion is a Boston-based cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. In July, 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced the creation of a new preclinical partnership to develop novel, next-generation therapeutics for the treatment of heart failure and cardiovascular diseases. The partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists in an entrepreneurial setting and enables the Discovery programs of Cardurion. In April 2018, Cardurion announced the Company entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. With recent evidence supporting that inhibition of PDE-9 has potential to restore heart-protective mechanisms that are dysfunctional in heart failure, CRD-733 has the potential to address the cell-signaling breakdown that contributes to the progression of heart failure.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $10M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  70. people using desktop computer inside office


  71. Resilience Therapeutics ($10M to $50M)

    Resilience Therapeutics is an operator of a drug discovery company intended to focus on developing small molecule therapeutics for psychiatric conditions. The company develops therapeutics that provide both symptom relief and potential disease modification for anxiety and trauma-related disorders. Its drug discovery engine focuses on developing therapeutics that provide both symptom relief and potential disease modification for PTSD and other Stress-Related Disorders, providing medical practitioners with therapeutics that provide both symptom relief and potential disease modification for anxiety and trauma-related disorders. Founded in 2014, Resilience Therapeutics is headquartered in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.5M raised in March, 2016
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  72. group of people sitting beside rectangular wooden table with laptops


  73. Farcast ($1M to $10M)

    Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $40M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  74. two men using computers


  75. CONTINUUS Pharmaceuticals (Less than $1M)

    CONTINUUS Pharmaceuticals works with pharmaceutical and generic companies under a Build-Own-Operate model. They design, build, and run the manufacturing process directly at the client site. This novel business model provides its clients with an exceptional, ”one-shop solution” for their entire development and manufacturing cycle. CONTINUUS Pharmaceuticals is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. In addition, the company is currently collaborating with hospital systems and pharmacy chains to establish its own generic business, where high-quality, low-cost drugs will be manufactured in the United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  76. Silicon Therapeutics (Less than $1M)

    Custom hardware means we have capability to write code for our speed/accuracy needs.Their software is specifically designed for high throughput drug discovery and design.

    • Less than $1M annual revenues
    • 51-100 employees
    • $6.2M raised in October, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  77. man in gray sweatshirt sitting on chair in front of iMac


  78. Entrega Bio (Less than $1M)

    Entrega Bio offers a proprietary technology that makes injectable substances available orally. Its technology has the potential to deliver a wide variety of biological molecules, drug substances, and nanoparticles. Entrega Bio collaborates with pharma and non-pharma industry partners to develop the platform for innovative therapeutic and diagnostic modalities. This platform enables novel applications in a variety of fields such as disease management and tracking in the burgeoning mobile health arena. Entrega Bio is based in Boston, Massachusetts, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in December, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  79. people sitting on black chairs


  80. Acetylon Pharmaceuticals ($1M to $10M)

    Acetylon Pharmaceuticals, Inc. intends to manufacture small molecule drugs to realize the therapeutic potential of histone deacetylase. The company was incorporated in 2008 and is based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $100M raised in July, 2013
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  81. people sitting in front of computer monitors


  82. QMENTA ($1M to $10M)

    QMENTA is a cloud-based medical image analysis and visualization platform that helps specialists provide better diagnosis and treatment for patients with brain diseases by quantifying changes in the patient’s brain. This helps to accelerate the discovery and development of new treatments for brain diseases. With QMENTA's cloud platform, specialists (researchers, neurologists, neurosurgeons, neuroradiologists) can upload medical images, have them processed, and access big datasets all in one place, within the browser, without the need to install and maintain any software. They can carry out advanced analyses with our proprietary tools and visualize the images with LeapMotion, thus we provide an intuitive, touch-less and sterilized way to bring these advanced imaging tools into the hands of the doctors, at the point of care, right in the operating room. Top-notch researchers all around the world have been using our platform that is infinitely scalable for data management, analysis, visualization, and sharing purposes. With our publicly accessible platform, you can advance your data and understanding of thousands, even millions of images. QMENTA is FDA Title 21 parts 11 & 820, Annex11, IEC 62304, GDPR, and HIPAA compliant. We take the privacy and security of patients data very seriously.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3.5M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  83. people sitting beside rectangular brown table with laptops


  84. Samsara Therapeutics ($1M to $10M)

    Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend healthy lifespan.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3.2M raised in December, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  85. people standiunmg


  86. Invetx ($10M to $50M)

    Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health. Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics. Working closely with best-in-class biotechnology companies, major investors and an extensive network of industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care. Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $10.3M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  87. Akouos ($1M to $10M)

    Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $105M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  88. selective focus photography of desk lamp on table


  89. TearClear ($1M to $10M)

    TearClear is a pharmaceutical company that specializes in providing a class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. The company was founded in 2015 and headquartered in California, United States.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $22M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  90. grey wooden table and black leather rolling chairs


  91. Alkeus Pharmaceuticals ($1M to $10M)

    Alkeus Pharmaceuticals Inc., a Boston-based startup focused on treatments for serious ophthalmic conditions.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in October, 2011
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  92. rectangular brown wooden table with chair lot inside building